23203-51-2

Upstream product

• 33214-39-0 4-m-Anisyl-4-methylvaleriansaeure 
• 4548-78-1 (3-methylbutyl)magnesium bromide 
• 874-90-8 4-methoxybenzonitrile 
• 21550-01-6 1-(4'-methoxyphenyl)-4-methylpentan-1-one 
• 33214-51-6 3-m-Anisyl-3-methyl-1-butylbrosylat 
• 23203-48-7 4-methyl-4-(p-methoxyphenyl)pentanoic acid 
• 4586-90-7 2-methyl-5-(4-methoxyphenyl)-2-pentanol 
• 64230-02-0 2-[1-hydroxy-meth-(Z)-ylidene]-4,4-dimethyl-cyclohexanone 
• 77630-12-7 2-formyl-4,4-dimethylcyclohex-2-en-1-one 
• 4255-62-3 4,4-dimethylcyclohexane-1-one 
• 1073-13-8 4,4-dimethylcyclohexenone 
• 29510-28-9 4-(p-Anisyl-4-methylpent-1-yl)-p-brombenzolsulfonat 
• 23203-50-1 1,1-dimethyl-7-methoxy-1,2,3,4-tetrahydronaphthalene 
• 94250-68-7 4,4-dimethyl-2-(hydroxymethylene)-3-<2-oxopropyl>cyclohexanone 

Downstream Products

• 1307812-32-3 5,5-dimethyl-3-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-4,5-dihydronaphtho[1,2-c]isoxazole-7-carbaldehyde 
• 1307812-31-2 5,5-dimethyl-3-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-7-vinyl-4,5-dihydronaphtho-[1,2-c]isoxazole 
• 1307809-53-5 1-((5,5-dimethyl-3-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-4,5-dihydronaphtho[1,2-c]isoxazol-7-yl)methyl)azetidine-3-carboxylic acid 
• 802021-53-0 6-Methoxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylamine 
• 53503-63-2 3,4-dihydro-6-methoxy-4,4-dimethyl-1,2-naphthalenedione, 2-oxime 

Relevant academic research and scientific papers

Iron-Catalyzed Synthesis of Dihydronaphthalenones from Aromatic Oxime Esters

Herein, a convenient procedure on iron-catalyzed radical-mediated synthesis of dihydronaphthalenones from oxime esters has been developed. By using iron salt as a green and inexpensive catalyst, various α-aryl oxime esters were transformed into the corresponding dihydronaphthalenones in moderate to good yields with high chemo-selectivities. The reaction proceeds via 1,5-hydrogen atom transfer and then intramolecular radical cyclization sequence. (Figure presented.).

HELIX 12 DIRECTED STEROIDAL PHARMACEUTICAL PRODUCTS

Compounds having the structure or their salts: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Some of these compounds having tissue-specific antiandrogenic activity and tissue-specific androgenic activity can be used to treat or reduce the risk of developing diseases related to loss of androgenic stimulation. Combinations with other active pharmaceutical agents are also disclosed.

Compounds having activity as inhibitors of cytochrome P450RAI

Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

Compounds having activity as inhibitors of cytochrome P450RAI

Compounds having Formula 2 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

Compounds having activity as inhibitors of cytochrome P450RAI

Compounds having Formula 8 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI

Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.

Compounds having activity as inhibitors of cytochrome P450RAI

Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

Annulation of α-Formyl α,β-Unsaturated Ketones by a Michael Addition-Cyclization Sequence. A Versatile Synthesis of Alicyclic Six-Membered Rings.

The potential generality of the annulation sequence shown in Scheme II (10 -> 11 -> 12 -> 13 -> 14/15) has been examined in model systems.Dehydrogenation of α-formylcyclohexanones 11a-d with 1 equiv of DDQ rapidly produces α,β-unsaturated α-formyl ketones